Clinical Trial Update: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) [Phase 3]

View source ↗

Summary

A Phase 3 recruitment update for CAMBRIA-2, a study of Camizestrant (AZD9833) as adjuvant endocrine therapy for ER+/HER2- early breast cancer, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Camizestrant

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, Early Breast Cancer | Phase 3 | Status: RECRUITING